Linking glycation and glycosylation with inflammation and mitochondrial dysfunction in Parkinson's disease

Frontiers in Neuroscience

Volumn 12, Issue JUN, 2018, Pages

  Videira, Paula A Q ^a   Castro Caldas, Margarida ^a,b  

^a UNIVERSIDADE NOVA DE LISBOA   (Portugal)

^b RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

Author keywords

Aging; Glycation; Glycosylation; Inflammation; Mitochondrial dysfunction; Parkinson's disease

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ALPHA SYNUCLEIN; GLYOXALASE; METHYLGLYOXAL; PARKIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PTEN INDUCED PUTATIVE KINASE 1; UNCLASSIFIED DRUG;

DISORDERS OF MITOCHONDRIAL FUNCTIONS; HUMAN; IMMUNE SYSTEM; INFLAMMATION; NEUROPATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; POLYSACCHARIDE STRUCTURE; PROTEIN GLYCOSYLATION; PROTEIN QUALITY; REVIEW;

EID: 85048250230     PISSN: 16624548     EISSN: 1662453X     Source Type: Journal    
DOI: 10.3389/fnins.2018.00381     Document Type: Review

References (213)

1. Abdelsalam, R. M., and Safar, M. M. (2015). Neuroprotective effects of vildagliptin in rat rotenone Parkinson's disease model: role of RAGE-NFκB and Nrf2-antioxidant signaling pathways. J. Neurochem. 133, 700-707. doi: 10.1111/jnc.13087
2. Aldini, G., Vistoli, G., Stefek, M., Chondrogianni, N., Grune, T., Sereikaite, J., et al. (2013). Molecular strategies to prevent, inhibit, and degrade advanced glycoxidation and advanced lipoxidation end products. Free Radic. Res. 47(Suppl. 1), 93-137. doi: 10.3109/10715762.2013.792926
3. Alexiou, P., Chatzopoulou, M., Pegklidou, K., and Demopoulos, V. J. (2010). RAGE: a multi-ligand receptor unveiling novel insights in health and disease. Curr. Med. Chem. 17, 2232-2252. doi: 10.2174/092986710791331086
4. Alfaro, J. F., Gong, C. X., Monroe, M. E., Aldrich, J. T., Clauss, T. R., Purvine, S. O., et al. (2012). Tandem mass spectrometry identifies many mouse brain O-GlcNAcylated proteins including EGF domain-specific O-GlcNAc transferase targets. Proc. Natl. Acad. Sci. U.S.A. 109, 7280-7285. doi: 10.1073/pnas.1200425109
5. Angelo, M. F., Aguirre, A., Aviles Reyes, R. X., Villarreal, A., Lukin, J., Melendez, M., et al. (2014). The proinflammatory RAGE/NF-kappaB pathway is involved in neuronal damage and reactive gliosis in a model of sleep apnea by intermittent hypoxia. PLoS One 9:e107901. doi: 10.1371/journal.pone.0107901
6. Apweiler, R., Hermjakob, H., and Sharon, N. (1999). On the frequency of protein glycosylation, as deduced from analysis of the SWISS-PROT database. Biochim. Biophys. Acta 1473, 4-8. doi: 10.1016/S0304-4165(99)00165-8
7. Arvanitakis, Z., Wilson, R. S., Bienias, J. L., and Bennett, D. A. (2007). Diabetes and parkinsonian signs in older persons. Alzheimer Dis. Assoc. Disord. 21, 144-149. doi: 10.1097/WAD.0b013e31805ba768
8. Baynes, J. W., and Thorpe, S. R. (2000). Glycoxidation and lipoxidation in atherogenesis. Free Radic. Biol. Med. 28, 1708-1716. doi: 10.1016/S0891-5849(00)00228-8
9. Becker, C., Brobert, G. P., Johansson, S., Jick, S. S., and Meier, C. R. (2008). Diabetes in patients with idiopathic Parkinson's disease. Diabetes Care 31, 1808-1812. doi: 10.2337/dc08-0479
10. Bierhaus, A., Schiekofer, S., Schwaninger, M., Andrassy, M., Humpert, P. M., Chen, J., et al. (2001). Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes Metab. Res. Rev. 50, 2792-2808
11. Bose, A., and Beal, M. F. (2016). Mitochondrial dysfunction in Parkinson's disease. J. Neurochem. 139(Suppl. 1), 216-231. doi: 10.1111/jnc.13731
12. Bousquet, M., St-Amour, I., Vandal, M., Julien, P., Cicchetti, F., and Calon, F. (2012). High-fat diet exacerbates MPTP-induced dopaminergic degeneration in mice. Neurobiol. Dis. 45, 529-538. doi: 10.1016/j.nbd.2011.09.009
13. Burnham-Marusich, A. R., and Berninsone, P. M. (2012). Multiple proteins with essential mitochondrial functions have glycosylated isoforms. Mitochondrion 12, 423-427. doi: 10.1016/j.mito.2012.04.004
14. Burre, J., Sharma, M., Tsetsenis, T., Buchman, V., Etherton, M. R., and Sudhof, T. C. (2010). Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science 329, 1663-1667. doi: 10.1126/science.1195227
15. Cabral, M. G., Silva, Z., Ligeiro, D., Seixas, E., Crespo, H., Carrascal, M. A., et al. (2013). The phagocytic capacity and immunological potency of human dendritic cells is improved by a2, 6-sialic acid deficiency. Immunology 138, 235-245. doi: 10.1111/imm.12025
16. Castro-Caldas, M., Carvalho, A. N., Rodrigues, E., Henderson, C. J., Wolf, C. R., Rodrigues, C. M. P., et al. (2012). Tauroursodeoxycholic acid prevents MPTP-induced dopaminergic cell death in a mouse model of Parkinson's disease. Mol. Neurobiol. 46, 475-486. doi: 10.1007/s12035-012-8295-4
17. Cebrián, C., Zucca, F. A., Mauri, P., Steinbeck, J. A., Studer, L., Scherzer, C. R., et al. (2014). MHC-I expression renders catecholaminergic neurons susceptible to T-cell-mediated degeneration. Nat. Commun. 5:3633. doi: 10.1038/ncomms4633
18. Cereda, E., Barichella, M., Cassani, E., Caccialanza, R., and Pezzoli, G. (2012). Clinical features of Parkinson disease when onset of diabetes came first: a case-control study. Neurology 78, 1507-1511. doi: 10.1212/WNL.0b013e3182553cc9
19. Chakraborty, J., Basso, V., and Ziviani, E. (2017). Post translational modification of Parkin. Biol. Direct 12:6. doi: 10.1186/s13062-017-0176-3
20. Chandra, N. C., Spiro, M. J., and Spiro, R. G. (1998). Identification of a glycoprotein from rat liver mitochondrial inner membrane and demonstration of its origin in the endoplasmic reticulum. J. Biol. Chem. 273, 19715-19721. doi: 10.1074/jbc.273.31.19715
21. Chaudhuri, K. R., Healy, D. G., and Schapira, A. H. (2006). Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol. 5, 235-245. doi: 10.1016/S1474-4422(06)70373-8
22. Chen, L., Mo, M., Li, G., Cen, L., Wei, L., Xiao, Y., et al. (2016). The biomarkers of immune dysregulation and inflammation response in Parkinson disease. Transl. Neurodegener. 5:16. doi: 10.1186/s40035-016-0063-3
23. Cho, H. J., Son, S. M., Jin, S. M., Hong, H. S., Shin, D. H., Kim, S. J., et al. (2009). RAGE regulates BACE1 and Aß generation via NFAT1 activation in Alzheimer's disease animal model. FASEB J. 23, 2639-2649. doi: 10.1096/fj.08-126383
24. Chu, C. T. (2011). Diversity in the regulation of autophagy and mitophagy: lessons from Parkinson's disease. Parkinson Dis. 2011:789431. doi: 10.4061/2011/789431
25. Chun, H. S., Gibson, G. E., DeGiorgio, L. A., Zhang, H., Kidd, V. J., and Son, J. H. (2001). Dopaminergic cell death induced by MPP+, oxidant and specific neurotoxicants shares the common molecular mechanism. J. Neurochem. 76, 1010-1021. doi: 10.1046/j.1471-4159.2001.00096.x
26. Ciechanover, A., and Kwon, Y. T. (2017). Protein quality control by molecular chaperones in neurodegeneration. Front. Neurosci. 11:185. doi: 10.3389/fnins.2017.00185
27. Cleeter, M. W. J., Cooper, J. M., and Schapira, A. H. V. (1992). Irreversible inhibition of mitochondrial complex I by 1-methyl-4-phenylpyridinium: evidence for free radical involvement. J. Neurochem. 58, 786-789. doi: 10.1111/j.1471-4159.1992.tb09789.x
28. Clements, C. M., McNally, R. S., Conti, B. J., Mak, T. W., and Ting, J. P. (2006). DJ-1, a cancer-and Parkinson's disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2. Proc. Natl. Acad. Sci. U.S.A. 103, 15091-15096. doi: 10.1073/pnas.0607260103
29. Conway, K. A., Lee, S. J., Rochet, J. C., Ding, T. T., Williamson, R. E., and Lansbury, P. T. Jr. (2000). Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl. Acad. Sci. U.S.A. 97, 571-576. doi: 10.1073/pnas.97.2.571
30. Cóppola-Segovia, V., Cavarsan, C., Maia, F. G., Ferraz, A. C., Nakao, L. S., Lima, M. M., et al. (2017). ER stress induced by tunicamycin triggers a-synuclein oligomerization, dopaminergic neurons death and locomotor impairment: a new model of Parkinson's disease. Mol. Neurobiol. 54, 5798-5806. doi: 10.1007/s12035-016-0114-x
31. Crespo, H. J., Lau, J. T., and Videira, P. A. (2013). Dendritic cells: a spot on sialic acid. Front. Immunol. 4:491. doi: 10.3389/fimmu.2013.00491
32. Dalfó, E., Portero-Otín, M., Ayala, V., Martínez, A., Pamplona, R., and Ferrer, I. (2005). Evidence of oxidative stress in the neocortex in incidental Lewy body disease. J. Neuropathol. Exp. Neurol. 64, 816-830. doi: 10.1097/01.jnen.0000179050.54522.5a
33. Dauer, W., and Przedborski, S. (2003). Parkinson's disease: mechanisms and models. Neuron 39, 889-909. doi: 10.1016/S0896-6273(03)00568-3
34. Dawson, T. M., and Dawson, V. L. (2003). Rare genetic mutations shed light on the pathogenesis of Parkinson disease. J. Clin. Invest. 111, 145-151. doi: 10.1172/JCI200317575
35. Dawson, T. M., and Dawson, V. L. (2010). The role of parkin in familial and sporadic Parkinson's disease. Mov. Disord. 25(Suppl. 1), 32-39. doi: 10.1002/mds.22798
36. Deane, R., Singh, I., Sagare, A. P., Bell, R. D., Ross, N. T., LaRue, B., et al. (2012). A multimodal RAGE-specific inhibitor reduces amyloid beta-mediated brain disorder in a mouse model of Alzheimer disease. J. Clin. Invest. 122, 1377-1392. doi: 10.1172/JCI58642
37. Deng, Y., Zhang, Y., Li, Y., Xiao, S., Song, D., Qing, H., et al. (2012). Occurrence and distribution of salsolinol-like compound, 1-acetyl-6, 7-dihydroxy-1, 2, 3, 4-tetrahydroisoquinoline (ADTIQ) in parkinsonian brains. J. Neural Transm. 119, 435-441. doi: 10.1007/s00702-011-0724-4
38. Dexter, D. T., and Jenner, P. (2013). Parkinson disease: from pathology to molecular disease mechanisms. Free Radic. Biol. Med. 62, 132-144. doi: 10.1016/j.freeradbiomed.2013.01.018
39. Ding, Q., and Keller, J. N. (2005). Evaluation of RAGE isoforms, ligands, and signaling in the brain. Biochim. Biophys. Acta 1746, 18-27. doi: 10.1016/j.bbamcr.2005.08.006
40. Donato, R. (2001). S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int. J. Biochem. Cell Biol. 33, 637-668. doi: 10.1016/S1357-2725(01)00046-2
41. Driver, J. A., Smith, A., Buring, J. E., Gaziano, J. M., Kurth, T., and Logroscino, G. (2008). Prospective cohort study of type 2 diabetes and the risk of Parkinson's disease. Diabetes Care 31, 2003-2005. doi: 10.2337/dc08-0688
42. Emanuele, E., D'Angelo, A., Tomaino, C., Binetti, G., Ghidoni, R., Politi, P., et al. (2005). Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia. Arch. Neurol. 62, 1734-1736. doi: 10.1001/archneur.62.11.1734
43. Fang, P., Schachner, M., and Shen, Y. (2012). HMGB1 in development and diseases of the central nervous system. Mol. Neurobiol. 45, 499-506. doi: 10.1007/s12035-012-8264-y
44. Fontana, L., Partridge, L., and Longo, V. D. (2010). Extending human life span-from yeast to humans. Science 328, 321-326. doi: 10.1126/science.1172539
45. Gao, H. M., Zhou, H., Zhang, F., Wilson, B. C., Kam, W., and Hong, J. S. (2011). HMGB1 acts on microglia Mac1 to mediate chronic neuroinflammation that drives progressive neurodegeneration. J. Neurosci. 31, 1081-1092. doi: 10.1523/JNEUROSCI.3732-10.2011
46. Gao, J., Teng, J., Liu, H., Han, X., Chen, B., and Xie, A. (2014). Association of RAGE gene polymorphisms with sporadic Parkinson's disease in Chinese Han population. Neurosci. Lett. 559, 158-162. doi: 10.1016/j.neulet.2013.11.038
47. Gao, X., Chen, H., Fung, T. T., Logroscino, G., Schwarzschild, M. A., Hu, F. B., et al. (2007). Prospective study of dietary pattern and risk of Parkinson disease. Am. J. Clin. Nutr. 86, 1486-1494. doi: 10.1093/ajcn/86.5.1486
48. Gasparotto, J., Ribeiro, C. T., Bortolin, R. C., Somensi, N., Rabelo, T. K., Kunzler, A., et al. (2017). Targeted inhibition of RAGE in substantia nigra of rats blocks 6-OHDA-induced dopaminergic denervation. Sci. Rep. 7:8795. doi: 10.1038/s41598-017-09257-3
49. Gizaw, S. T., Koda, T., Amano, M., Kamimura, K., Ohashi, T., Hinou, H., et al. (2015). A comprehensive glycome profiling of Huntington's disease transgenic mice. Biochim. Biophys. Acta 1850, 1704-1718. doi: 10.1016/j.bbagen.2015.04.006
50. Gizaw, S. T., Ohashi, T., Tanaka, M., Hinou, H., and Nishimura, S. (2016). Glycoblotting method allows for rapid and efficient glycome profiling of human Alzheimer's disease brain, serum and cerebrospinal fluid towards potential biomarker discovery. Biochim. Biophys. Acta 1860, 1716-1727. doi: 10.1016/j.bbagen.2016.03.009
51. Guerrero, E., Vasudevaraju, P., Hegde, M. L., Britton, G. B., and Rao, K. S. (2013). Recent advances in a-synuclein functions, advanced glycation, and toxicity: implications for Parkinson's disease. Mol. Neurobiol. 47, 525-536. doi: 10.1007/s12035-012-8328-z
52. Hagglund, P., Bunkenborg, J., Elortza, F., Jensen, O. N., and Roepstorff, P. (2004). A new strategy for identification of N-glycosylated proteins and unambiguous assignment of their glycosylation sites using HILIC enrichment and partial deglycosylation. J. Proteome Res. 3, 556-566. doi: 10.1021/pr034112b
53. Hald, A., and Lotharius, J. (2005). Oxidative stress and inflammation in Parkinson's disease: is there a causal link? Exp. Neurol. 193, 279-290. doi: 10.1016/j.expneurol.2005.01.013
54. Halliday, G. M., and Stevens, C. H. (2011). Glia: initiators and progressors of pathology in Parkinson's disease. Mov. Disord. 26, 6-17. doi: 10.1002/mds.23455
55. Haltiwanger, R. S., and Lowe, J. B. (2004). Role of glycosylation in development. Annu. Rev. Biochem. 73, 491-537. doi: 10.1146/annurev.biochem.73.011303.074043
56. Hastrup, H., Karlin, A., and Javitch, J. A. (2001). Symmetrical dimer of the human dopamine transporter revealed by cross-linking Cys-306 at the extracellular end of the sixth transmembrane segment. Proc. Natl. Acad. Sci. U.S.A. 98, 10055-10060. doi: 10.1073/pnas.181344298
57. Hatakeyama, S., Amano, M., Tobisawa, Y., Yoneyama, T., Tsuchiya, N., Habuchi, T., et al. (2014). Serum N-glycan alteration associated with renal cell carcinoma detected by high-throughput glycan analysis. J. Urol. 191, 805-813. doi: 10.1016/j.juro.2013.10.052
58. Hebert, G., Arsaut, J., Dantzer, R., and Demotes-Mainard, J. (2003). Time-course of the expression of inflammatory cytokines and matrix metalloproteinases in the striatum and mesencephalon of mice injected with 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine, a dopaminergic neurotoxin. Neurosci. Lett. 349, 191-195. doi: 10.1016/S0304-3940(03)00832-2
59. Hirsch, E. C., Breidert, T., Rousselet, E., Hunot, S., Hartmann, A., and Michel, P. P. (2003). The role of glial reaction and inflammation in Parkinson's disease. Ann. N.Y. Acad. Sci. 991, 214-228. doi: 10.1111/j.1749-6632.2003.tb07478.x
60. Hirsch, E. C., Jenner, P., and Przedborski, S. (2013). Pathogenesis of Parkinson's disease. Mov. Disord. 28, 24-30. doi: 10.1002/mds.25032
61. Hofmann, M. A., Drury, S., Fu, C., Qu, W., Taguchi, A., Lu, Y., et al. (1999). RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 97, 889-901. doi: 10.1016/S0092-8674(00)80801-6
62. Holtz, W. A., and O'Malley, K. L. (2003). Parkinsonian mimetics induce aspects of unfolded protein response in death of dopaminergic neurons. J. Biol. Chem. 278, 19367-19377. doi: 10.1074/jbc. M211821200
63. Hoozemans, J. J., van Haastert, E. S., Eikelenboom, P., de Vos, R. A., Rozemuller, J. M., and Scheper, W. (2007). Activation of the unfolded protein response in Parkinson's disease. Biochem. Biophys. Res. Commun. 354, 707-711. doi: 10.1016/j.bbrc.2007.01.043
64. Hu, Y., Suarez, J., Fricovsky, E., Wang, H., Scott, B. T., Trauger, S. A., et al. (2009). Increased enzymatic O-GlcNAcylation of mitochondrial proteins impairs mitochondrial function in cardiac myocytes exposed to high glucose. J. Biol. Chem. 284, 547-555. doi: 10.1074/jbc. M808518200
65. Huttunen, H. J., Kuja-Panula, J., and Rauvala, H. (2002). Receptor for advanced glycation end products (RAGE) signaling induces CREB-dependent chromogranin expression during neuronal differentiation. J. Biol. Chem. 277, 38635-38646. doi: 10.1074/jbc. M202515200
66. Ishibashi, Y., Tobisawa, Y., Hatakeyama, S., Ohashi, T., Tanaka, M., Narita, S., et al. (2014). Serum tri-and tetra-antennary N-glycan is a potential predictive biomarker for castration-resistant prostate cancer. Prostate 74, 1521-1529. doi: 10.1002/pros.22869
67. Jankovic, J. (2008). Parkinson's disease: clinical features and diagnosis. J. Neurol. Neurosurg. Psychiatry 79, 368-376. doi: 10.1136/jnnp.2007.131045
68. Jiang, H., Jiang, Q., and Feng, J. (2004). Parkin increases dopamine uptake by enhancing the cell surface expression of dopamine transporter. J. Biol. Chem. 279, 54380-54386. doi: 10.1074/jbc. M409282200
69. Jiang, H., Kang, S. U., Zhang, S., Karuppagounder, S., Xu, J., Lee, Y. K., et al. (2016). Adult conditional knockout of PGC-1a leads to loss of dopamine neurons. eNeuro 3:ENEURO.0183-16.2016. doi: 10.1523/ENEURO.0183-16.2016
70. Kalea, A. Z., Schmidt, A. M., and Hudson, B. I. (2011). Alternative splicing of RAGE: roles in biology and disease. Front. Biosci. 16, 2756-2770. doi: 10.2741/3884
71. Kameyama, A., Nakaya, S., Ito, H., Kikuchi, N., Angata, T., Nakamura, M., et al. (2006). Strategy for simulation of CID spectra of N-linked oligosaccharides toward glycomics. J. Proteome Res. 5, 808-814. doi: 10.1021/pr0503937
72. Kamiyama, T., Yokoo, H., Furukawa, J. I., Kurogochi, M., Togashi, T., Miura, N., et al. (2013). Identification of novel serum biomarkers of hepatocellular carcinoma using glycomic analysis. Hepatology 57, 2314-2325. doi: 10.1002/hep.26262
73. Kannarkat, G. T., Boss, J. M., and Tansey, M. G. (2013). The role of innate and adaptive immunity in Parkinson's disease. J. Parkinsons Dis. 3, 493-514. doi: 10.3233/JPD-130250
74. Keane, P. C., Kurzawa, M., Blain, P. G., and Morris, C. M. (2011). Mitochondrial dysfunction in Parkinson's disease. Parkinsons Dis. 2011:716871. doi: 10.4061/2011/716871
75. Keeney, P. M., Xie, J., Capaldi, R. A., and Bennett, J. P. (2006). Parkinson's disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled. J. Neurosci. 26, 5256-5264. doi: 10.1523/JNEUROSCI.0984-06.2006
76. Kim, S. W., Lim, C. M., Kim, J. B., Shin, J. H., Lee, S., Lee, M., et al. (2011). Extracellular HMGB1 released by NMDA treatment confers neuronal apoptosis via RAGE-p38 MAPK/ERK signaling pathway. Neurotoxicol. Res. 20, 159-169. doi: 10.1007/s12640-010-9231-x
77. Kislinger, T., Fu, C., Huber, B., Qu, W., Taguchi, A., Du Yan, S., et al. (1999). Nepsilon-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J. Biol. Chem. 274, 31740-31749. doi: 10.1074/jbc.274.44.31740
78. Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., et al. (1998). Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392, 605-608. doi: 10.1038/33416
79. Klein, C., and Westenberger, A. (2012). Genetics of Parkinson's disease. Cold Spring Harb. Perspect. Med. 2:a008888. doi: 10.1101/cshperspect.a008888
80. Kortekaas, R., Leenders, K. L., van Oostrom, J. C., Vaalburg, W., Bart, J., Willemsen, A. T., et al. (2005). Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann. Neurol. 57, 176-179. doi: 10.1002/ana.20369
81. Kuhla, B., Boeck, K., Luth, H. J., Schmidt, A., Weigle, B., Schmitz, M., et al. (2006). Age-dependent changes of glyoxalase expression in human brain. Neurobiol. Aging 27, 815-822. doi: 10.1016/j.neurobiolaging.2005.04.006
82. Kung, L. A., Tao, S. C., Qian, J., Smith, M. G., Snyder, M., and Zhu, H. (2009). Global analysis of the glycoproteome in Saccharomyces cerevisiae reveals new roles for protein glycosylation in eukaryotes. Mol. Syst. Biol. 5:308. doi: 10.1038/msb.2009.64
83. Kurz, A., Rabbani, N., Walter, M., Bonin, M., Thornalley, P., Auburger, G., et al. (2011). Alpha-synuclein deficiency leads to increased glyoxalase I expression and glycation stress. Cell. Mol. Life Sci. 68, 721-733. doi: 10.1007/s00018-010-0483-7
84. Lee, J. Y., Song, J., Kwon, K., Jang, S., Kim, C., Baek, K., et al. (2012). Human DJ-1 and its homologs are novel glyoxalases. Hum. Mol. Genet. 21, 3215-3225. doi: 10.1093/hmg/dds155
85. Lee, V. M., and Trojanowski, J. Q. (2006). Mechanisms of Parkinson's disease linked to pathological alpha synuclein: new targets for drug discovery. Neuron 52, 33-38. doi: 10.1016/j.neuron.2006.09.026
86. Leroy, E., Boyer, R., Auburger, G., Leube, B., Ulm, G., Mezey, E., et al. (1998). The ubiquitin pathway in Parkinson's disease. Nature 395, 451-452. doi: 10.1038/26652
87. Levrat, C., Louisot, P., and Morelis, R. (1989). Distribution of glycosyltransferase activities in different compartments of mitochondria. Biochem. Int. 18, 813-823
88. Li, J., Liu, D., Sun, L., Lu, Y., and Zhang, Z. (2012). Advanced glycation end products and neurodegenerative diseases: mechanisms and perspective. J. Neurol. Sci. 317, 1-5. doi: 10.1016/j.jns.2012.02.018
89. Li, L. B., Chen, N., Ramamoorthy, S., Chi, L., Cui, X. N., Wang, L. C., et al. (2004). The role of N-glycosylation in function and surface trafficking of the human dopamine transporter. J. Biol. Chem. 279, 21012-21020. doi: 10.1074/jbc. M311972200
90. Linnartz, B., Bodea, L. G., and Neumann, H. (2012). Microglial carbohydrate-binding receptors for neural repair. Cell Tissue Res. 349, 215-227. doi: 10.1007/s00441-012-1342-7
91. Linnartz-Gerlach, B., Kopatz, J., and Neumann, H. (2014). Siglec functions of microglia. Glycobiology 24, 794-799. doi: 10.1093/glycob/cwu044
92. Lipman, I. J., Boykin, M. E., and Flora, R. E. (1974). Glucose intolerance in Parkinson's disease. J. Chronic Dis. 27, 573-579. doi: 10.1016/0021-9681(74)90031-9
93. Liu, K., Shi, N., Sun, Y., Zhang, T., and Sun, X. (2013). Therapeutic effects of rapamycin on MPTP-induced Parkinsonism in mice. Neurochem. Res. 38, 201-207. doi: 10.1007/s11064-012-0909-8
94. Louveau, A., Smirnov, I., Keyes, T. J., Eccles, J. D., Rouhani, S. J., Peske, J. D., et al. (2015). Structural and functional features of central nervous system lymphatic vessels. Nature 523, 337-341. doi: 10.1038/nature14432
95. Lowe, J. B., and Marth, J. D. (2003). A genetic approach to Mammalian glycan function. Annu. Rev. Biochem. 72, 643-691. doi: 10.1146/annurev.biochem.72.121801.161809
96. Lu, L., Fu, D. L., Li, H. Q., Liu, A. J., Li, J. H., and Zheng, G. Q. (2014). Diabetes and risk of Parkinson's disease: an updated meta-analysis of case control studies. PLoS One 9:e85781. doi: 10.1371/journal.pone.0085781
97. Ma, D., Shuler, J. M., Raider, K. D., Rogers, R. S., Wheatley, J. L., Geiger, P. C., et al. (2015). Effects of discontinuing a high-fat diet on mitochondrial proteins and 6-hydroxydopamine-induced dopamine depletion in rats. Brain Res. 1613, 49-58. doi: 10.1016/j.brainres.2015.03.053
98. Marotta, N. P., Lin, Y. H., Lewis, Y. E., Ambroso, M. R., Zaro, B. W., Roth, M. T., et al. (2015). O-GlcNAc modification blocks the aggregation and toxicity of the protein a-synuclein associated with Parkinson's disease. Nat. Chem. 7, 913-920. doi: 10.1038/nchem.2361
99. Martin, H. L., Santoro, M., Mustafa, S., Riedel, G., Forrester, J. V., and Teismann, P. (2016). Evidence for a role of adaptive immune response in the disease pathogenesis of the MPTP mouse model of Parkinson's disease. Glia 64, 386-395. doi: 10.1002/glia.22935
100. Martin, I., Dawson, V. L., and Dawson, T. M. (2011). Recent advances in the genetics of Parkinson's disease. Annu. Rev. Genomics Hum. Genet. 12, 301-325. doi: 10.1146/annurev-genom-082410-101440
101. Martinez, Z., Zhu, M., Han, S., and Fink, A. L. (2007). GM1 specifically interacts with a-synuclein and inhibits fibrillation. Biochemistry 46, 1868-1877. doi: 10.1021/bi061749a
102. Matheoud, D., Sugiura, A., Bellemare-Pelletier, A., Laplante, A., Rondeau, C., Chemali, M., et al. (2016). Parkinson's disease-related proteins PINK1 and parkin repress mitochondrial antigen presentation. Cell 166, 314-327. doi: 10.1016/j.cell.2016.05.039
103. McCoy, M. K., Ruhn, K. A., Blesch, A., and Tansey, M. G. (2011). TNF: a key neuroinflammatory mediator of neurotoxicity and neurodegeneration in models of Parkinson's disease. Adv. Exp. Med. Biol. 691, 539-540. doi: 10.1007/978-1-4419-6612-4_56
104. McGeer, P. L., and McGeer, E. G. (2008). Glial reactions in Parkinson's disease. Mov. Disord. 23, 474-483. doi: 10.1002/mds.21751
105. McNaught, K. S., and Jenner, P. (2001). Proteasomal function is impaired in substantia nigra in Parkinson's disease. Neurosci. Lett. 297, 191-194. doi: 10.1016/S0304-3940(00)01701-8
106. Menzies, F. M., Fleming, A., and Rubinsztein, D. C. (2015). Compromised autophagy and neurodegenerative diseases. Nat. Rev. Neurosci. 16, 345-357. doi: 10.1038/nrn3961
107. Mercado, G., Valdés, P., and Hetz, C. (2013). An ERcentric view of Parkinson's disease. Trends Mol. Med. 19, 165-175. doi: 10.1016/j.molmed.2012.12.005
108. Mihoub, M., Abdallah, J., Gontero, B., Dairou, J., and Richarme, G. (2015). The DJ-1 superfamily member Hsp31 repairs proteins from glycation by methylglyoxal and glyoxal. Biochem. Biophys. Res. Commun. 463, 1305-1310. doi: 10.1016/j.bbrc.2015.06.111
109. Mizuno, Y., Ohta, S., Tanaka, M., Takamiya, S., Suzuki, K., Sato, T., et al. (1989). Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. Biochem. Biophys. Res. Commun. 163, 1450-1455. doi: 10.1016/0006-291X(89)91141-8
110. Mogi, M., Harada, M., Kondo, T., Riederer, P., Inagaki, H., Minami, M., et al. (1994). Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci. Lett. 180, 147-150. doi: 10.1016/0304-3940(94)90508-8
111. Moore, D. J., West, A. B., Dawson, V. L., and Dawson, T. M. (2005). Molecular pathophysiology of Parkinson's disease. Annu. Rev. Neurosci. 28, 57-87. doi: 10.1146/annurev.neuro.28.061604.135718
112. More, S. V., Kumar, H., Kim, I. S., Song, S. Y., and Choi, D. K. (2013). Cellular and molecular mediators of neuroinflammation in the pathogenesis of Parkinson's disease. Med. Inflamm. 2013:952375. doi: 10.1155/2013/952375
113. Moreira, S., Fonseca, I., Nunes, M. J., Rosa, A., Lemos, L., Rodrigues, E., et al. (2017). Nrf2 activation by tauroursodeoxycholic acid in experimental models of Parkinson's disease. Exp. Neurol. 295, 77-87. doi: 10.1016/j.expneurol.2017.05.009
114. Mosley, R. L., Hutter-Saunders, J. A., Stone, D. K., and Gendelman, H. E. (2012). Inflammation and adaptive immunity in Parkinson's disease. Cold Spring Harb. Perspect. Med. 2:a009381. doi: 10.1101/cshperspect.a009381
115. Münch, G., Lüth, H. J., Wong, A., Arendt, T., Hirsch, E., Ravid, R., et al. (2000). Crosslinking of alpha synuclein by advanced glycation end products-an early pathophysiological step in Lewy body formation? J. Chem. Neuroanat. 20, 253-257. doi: 10.1016/S0891-0618(00)00096-X
116. Naeem, S., Ikram, R., Khan, S. S., and Rao, S. S. (2017). NSAIDs ameliorate cognitive and motor impairment in a model of parkinsonism induced by chlorpromazine. Pak. J. Pharm. Sci. 30, 801-808
117. Nalivaeva, N. N., and Turner, A. J. (2001). Post-translational modifications of proteins: acetylcholinesterase as a model system. Proteomics 1, 735-747. doi: 10.1002/1615-9861(200106)1:6<735::AID-PROT735>3.0.CO;2-8
118. Neeper, M., Schmidt, A. M., Brett, J., Yan, S. D., Wang, F., Pan, Y. C., et al. (1992). Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J. Biol. Chem. 267, 14998-15004
119. Nemani, V. M., Lu, W., Berge, V., Nakamura, K., Onoa, B., Lee, M. K., et al. (2010). Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron 65, 66-79. doi: 10.1016/j.neuron.2009.12.023
120. Nicotra, A., and Parvez, S. H. (2002). Apoptotic molecules and MPTP-induced cell death. Neurotoxicol. Teratol. 24, 599-605. doi: 10.1016/S0892-0362(02)00213-1
121. Nishimura, S.-I. (2011). Toward automated glycan analysis. Adv. Carbohydr. Chem. Biochem. 65, 219-271. doi: 10.1016/B978-0-12-385520-6.00005-4
122. Nouso, K., Amano, M., Miyahara, K., Ito, M. I., Morimoto, Y., Kato, H., et al. (2013). Clinical utility of high-throughput glycome analysis in patients with pancreatic cancer. J. Gastroenterol. 48, 1171-1179. doi: 10.1007/s00535-012-0732-7
123. Nuytemans, K., Theuns, J., Cruts, M., and Van Broeckhoven, C. (2010). Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update. Hum. Mutat. 31, 763-780. doi: 10.1002/humu.21277
124. Ohtsubo, K., and Marth, J. D. (2006). Glycosylation in cellular mechanisms of health and disease. Cell 126, 855-867. doi: 10.1016/j.cell.2006.08.019
125. Outeiro, T. F., Klucken, J., Bercury, K., Tetzlaff, J., Putcha, P., Oliveira, L. M., et al. (2009). Dopamine-induced conformational changes in alpha-synuclein. PLoS One 4:e6906. doi: 10.1371/journal.pone.0006906
126. Padmaraju, V., Bhaskar, J. J., Prasada Rao, U. J., Salimath, P. V., and Rao, K. S. (2011). Role of advanced glycation on aggregation and DNA binding properties of alpha-synuclein. J. Alzheimers Dis. 24, 211-221. doi: 10.3233/JAD-2011-101965
127. Park, J. S., Ji, I. J., An, H. J., Kang, M. J., Kang, S. W., Kim, D. H., et al. (2015). Disease associated mutations of TREM2 alter the processing of N-linked oligosaccharides in the golgi apparatus. Traffic 16, 510-518. doi: 10.1111/tra.12264
128. Pattarini, R., Smeyne, R. J., and Morgan, J. I. (2007). Temporal mRNA profiles of inflammatory mediators in the murine 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyrimidine model of Parkinson's disease. Neuroscience 145, 654-668. doi: 10.1016/j.neuroscience.2006.12.030
129. Pekkurnaz, G., Trinidad, J. C., Wang, X., Kong, D., and Schwarz, T. L. (2014). Glucose regulates mitochondrial motility via Milton modification by O-GlcNAc transferase. Cell 158, 54-68. doi: 10.1016/j.cell.2014.06.007
130. Perry, G., Moreira, P. I., Siedlak, S. L., Nunomura, A., Zhu, X., and Smith, M. A. (2009). Natural oxidant balance in Parkinson disease. Arch. Neurol. 66:1445. doi: 10.1001/archneurol.2009.261
131. Pfaff, D. H., Fleming, T., Nawroth, P., and Teleman, A. A. (2017). Evidence against a role for the Parkinsonism-associated protein DJ-1 in methylglyoxal detoxification. J. Biol. Chem. 292, 685-690. doi: 10.1074/jbc. M116.743823
132. Poewe, W., Seppi, K., Tanner, C. M., Halliday, G. M., Brundin, P., Volkmann, J., et al. (2017). Parkinson disease. Nat. Rev. Dis. Primers 3:17013. doi: 10.1038/nrdp.2017.13
133. Przedborski, S., Tieu, K., Perier, C., and Vila, M. (2004). MPTP as a mitochondrial neurotoxin model of Parkinson's disease. J. Bioenerg. Biomembr. 36, 375-379. doi: 10.1023/B:JOBB.0000041771.66775.d5
134. Rabbani, N., and Thornalley, P. J. (2008). Dicarbonyls linked to damage in the powerhouse: glycation of mitochondrial proteins and oxidative stress. Biochem. Soc. Trans. 36(Pt 5), 1045-1050. doi: 10.1042/BST0361045
135. Rabbani, N., and Thornalley, P. J. (2012). Methylglyoxal, glyoxalase 1 and the dicarbonyl proteome. Amino Acids 42, 1133-1142. doi: 10.1007/s00726-010-0783-0
136. Rayaprolu, S., Mullen, B., Baker, M., Lynch, T., Finger, E., Seeley, W. W., et al. (2013). TREM2 in neurodegeneration: evidence for association of the p. R47H variant with frontotemporal dementia and Parkinson's disease. Mol. Neurodegener. 8:19. doi: 10.1186/1750-1326-8-19
137. Requejo-Aguilar, R., Lopez-Fabuel, I., Fernandez, E., Martins, L. M., Almeida, A., and Bolaños, J. P. (2014). PINK-1 deficiency sustains cell proliferation by reprogramming glucose metabolism through HIF1. Nat. Commun. 24:4514. doi: 10.1038/ncomms5514
138. Requejo-Aguilar, R., Lopez-Fabuel, I., Jimenez-Blasco, D., Fernandez, E., Almeida, A., and Bolaños, J. P. (2015). DJ1 represses glycolysis and cell proliferation by transcriptionally up-regulating Pink1. Biochem. J. 467, 303-310. doi: 10.1042/BJ20141025
139. Richarme, G., Mihoub, M., Dairou, J., Bui, L. C., Leger, T., and Lamouri, A. (2015). Parkinsonism-associated protein DJ-1/Park7 is a major protein deglycase that repairs methylglyoxal-and glyoxal-glycated cysteine, arginine, and lysine residues. J. Biol. Chem. 290, 1885-1897. doi: 10.1074/jbc. M114.597815
140. Rosa, A. I., Duarte-Silva, S., Silva-Fernandes, A., Nunes, M. J., Carvalho, A. N., Rodrigues, E., et al. (2018). Tauroursodeoxycholic acid improves motor symptoms in a mouse model of Parkinson's disease. Mol. Neurobiol. doi: 10.1007/s12035-018-1062-4 [Epub ahead of print]
141. Rosa, A. I., Fonseca, I., Nunes, M. J., Moreira, S., Rodrigues, E., Carvalho, A. N., et al. (2017). Novel insights into the antioxidant role of tauroursodeoxycholic acid in experimental models of Parkinson's disease. Biochim. Biophys. Acta 1863, 2171-2181. doi: 10.1016/j.bbadis.2017.06.004
142. Rosca, M. G., Mustata, T. G., Kinter, M. T., Ozdemir, A. M., Kern, T. S., Szweda, L. I., et al. (2005). Glycation of mitochondrial proteins from diabetic rat kidney is associated with excess superoxide formation. Am. J. Physiol. Renal Physiol. 289, F420-F430. doi: 10.1152/ajprenal.00415.2004
143. Rotermund, C., Truckenmuller, F. M., Schell, H., and Kahle, P. J. (2014). Diet induced obesity accelerates the onset of terminal phenotypes in alpha-synuclein transgenic mice. J. Neurochem. 31, 848-858. doi: 10.1111/jnc.12813
144. Russell, A. C., Šimurina, M., Garcia, M. T., Novokmet, M., Wang, Y., Rudan, I., et al. (2017). The N-glycosylation of immunoglobulin G as a novel biomarker of Parkinson's disease. Glycobiology 27, 501-510. doi: 10.1093/glycob/cwx022
145. Salahuddin, P., Rabbani, G., and Khan, R. H. (2014). The role of advanced glycation end products in various types of neurodegenerative disease: a therapeutic approach. Cell. Mol. Biol. Lett. 19, 407-437. doi: 10.2478/s11658-014-0205-5
146. Sandyk, R. (1993). The relationship between diabetes mellitus and Parkinson's disease. Int. J. Neurosci. 69, 125-130. doi: 10.3109/00207459309003322
147. Santiago, J. A., and Potashkin, J. A. (2014). Current challenges towards the development of a blood test for Parkinson's disease. Diagnostics 4, 153-164. doi: 10.3390/diagnostics4040153
148. Santoro, M., Maetzler, W., Stathakos, P., Martin, H. L., Hobert, M. A., Rattay, T. W., et al. (2016). In-vivo evidence that high mobility group box 1 exerts deleterious effects in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine model and Parkinson's disease which can be attenuated by glycyrrhizin. Neurobiol. Dis. 91, 59-68. doi: 10.1016/j.nbd.2016.02.018
149. Sasaki, T., Liu, K., Agari, T., Yasuhara, T., Morimoto, J., Okazaki, M., et al. (2016). Anti-high mobility group box 1 antibody exerts neuroprotection in a rat model of Parkinson's disease. Exp. Neurol. 275, 220-231. doi: 10.1016/j.expneurol.2015.11.003
150. Sathe, K., Maetzler, W., Lang, J. D., Mounsey, R. B., Fleckenstein, C., Martin, H. L., et al. (2012). S100B is increased in Parkinson's disease and ablation protects against MPTP induced toxicity through the RAGE and TNF-alpha pathway. Brain 135(Pt 11), 3336-3347. doi: 10.1093/brain/aws250
151. Schaf, D. V., Tort, A. B., Fricke, D., Schestatsky, P., Portela, L. V., Souza, D. O., et al. (2005). S100B and NSE serum levels in patients with parkinson's disease. Parkinsonism Relat. Disord. 11, 39-43. doi: 10.1016/j.parkreldis.2004.07.002
152. Schapira, A. H. (1994). Mitochondrial function and neurotoxicity. Curr. Opin. Neurol. 7, 531-534. doi: 10.1097/00019052-199412000-00010
153. Schapira, A. H. (2012). Targeting mitochondria for neuroprotection in Parkinson's disease. Antioxid. Redox Signal. 16, 965-973. doi: 10.1089/ars.2011.4419
154. Schapira, A. H., Cooper, J. M., Dexter, D., Clark, J. B., Jenner, P., and Marsden, C. D. (1990). Mitochondrial complex I #eficiency in Parkinson s disease. J. Neurochem. 54, 823-827. doi: 10.1111/j.1471-4159.1990.tb02325.x
155. Schneider, J. S., Kean, A., and DiStefano, L. (1995). GM1 ganglioside rescues substantia nigra pars compacta neurons and increases dopamine synthesis in residual nigrostriatal dopaminergic neurons in MPTP-treated mice. J. Neurosci. Res. 42, 117-123. doi: 10.1002/jnr.490420113
156. Schwab, R. S. (1960). Progression and prognosis in Parkinson's disease. J. Nerv. Ment. Dis. 130, 556-566. doi: 10.1097/00005053-196006000-00017
157. Shimura, H., Schlossmacher, M. G., Hattori, N., Frosch, M. P., Trockenbacher, A., Schneider, R., et al. (2001). Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science 293, 263-269. doi: 10.1126/science.1060627
158. Shin, J. H., Ko, H. S., Kang, H., Lee, Y., Lee, Y. I., Pletinkova, O., et al. (2011). PARIS (ZNF746) repression of PGC-1a contributes to neurodegeneration in Parkinson's disease. Cell 144, 689-702. doi: 10.1016/j.cell.2011.02.010
159. Silva, M., Silva, Z., Marques, G., Ferro, T., Gonçalves, M., Monteiro, M., et al. (2016). Sialic acid removal from dendritic cells improves antigen cross-presentation and boosts anti-tumor immune responses. Oncotarget 7, 41053-41066. doi: 10.18632/oncotarget.9419
160. Silva, R. M., Ries, V., Oo, T. F., Yarygina, O., Jackson, V., Ryu, E. J., et al. (2005). CHOP/GADD153 is a mediator of apoptotic death in substantia nigra dopamine neurons in an in vivo neurotoxin model of parkinsonism. J. Neurochem. 95, 974-986. doi: 10.1111/j.1471-4159.2005.03428.x
161. Silvestri, L., Caputo, V., Bellacchio, E., Atorino, L., Dallapiccola, B., Valenteet, E. M., et al. (2005). Mitochondrial import and enzymatic activity of PINK1 mutants associated to recessive parkinsonism. Hum. Mol. Genet. 14, 3477-3492. doi: 10.1093/hmg/ddi377
162. Silveyra, M. X., Cuadrado-Corrales, N., Marcos, A., Barquero, M. S., Rábano, A., Calero, M., et al. (2006). Altered glycosylation of acetylcholinesterase in Creutzfeldt-Jakob disease. J. Neurochem. 96, 97-104. doi: 10.1111/j.1471-4159.2005.03514.x
163. Song, D. W., Xin, N., Xie, B. J., Li, Y. J., Meng, L. Y., Li, H. M., et al. (2014). Formation of a salsolinol-like compound, the neurotoxin, 1-acetyl-6, 7-dihydroxy-1, 2, 3, 4-tetrahydroisoquinoline, in a cellular model of hyperglycemia and a rat model of diabetes. Int. J. Mol. Med. 33, 736-742. doi: 10.3892/ijmm.2013.1604
164. Song, S., Jang, S., Park, J., Bang, S., Choi, S., Kwon, K. Y., et al. (2013). Characterization of PINK1 (PTEN-induced putative kinase 1) mutations associated with parkinson disease in mammalian cells and drosophila. J. Biol. Chem. 288, 5660-5672. doi: 10.1074/jbc. M112.430801
165. Spiro, R. G. (2002). Protein glycosylation: nature, distribution, enzymatic formation, and disease implications of glycopeptide bonds. Glycobiology 12, 43R-56R. doi: 10.1093/glycob/12.4.43R
166. Sriram, K., Benkovic, S. A., Hebert, M. A., Miller, D. B., and O'Callaghan, J. P. (2004). Induction of gp130-related cytokines and activation of JAK2/STAT3 pathway in astrocytes precedes up-regulation of glial fibrillary acidic protein in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine model of neurodegeneration: key signaling pathway for astrogliosis in vivo? J. Biol. Chem. 279, 19936-19947. doi: 10.1074/jbc. M309304200
167. Stanley, P., Schachter, H., Taniguchi, N., et al. (2009). "N-Glycans, "in Essentials of Glycobiology, 2nd Edn, eds A. Varki, R. Cummings, and J. Esko (Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press)
168. Storch, A., Ludolph, A. C., and Schwarz, J. (2004). Dopamine transporter: involvement in selective dopaminergic neurotoxicity and degeneration. J. Neural Transm. 111, 1267-1286. doi: 10.1007/s00702-004-0203-2
169. Sui, Y. T., Bullock, K. M., Erickson, M. A., Zhang, J., and Banks, W. A. (2014). Alpha synuclein is transported into and out of the brain by the blood-brain barrier. Peptides 62, 197-202. doi: 10.1016/j.peptides.2014.09.018
170. Sweeney, M. D., Sagare, A. P., and Zlokovic, B. V. (2018). Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nat. Rev. Neurol. 14, 133-150. doi: 10.1038/nrneurol.2017.188
171. Takata, K., Takada, T., Ito, A., Asai, M., Tawa, M., Saito, Y., et al. (2012). Microglial amyloid-ß 1-40 phagocytosis dysfunction is caused by high-mobility group box protein-1: implications for the pathological progression of Alzheimer's disease. Int. J. Alzheimers Dis. 2012:685739. doi: 10.1155/2012/685739
172. Tanaka, N., Yonekura, H., Yamagishi, S., Fujimori, H., Yamamoto, Y., and Yamamoto, H. (2000). The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells. J. Biol. Chem. 275, 25781-25790. doi: 10.1074/jbc. M001235200
173. Tang, Y., and Le, W. (2016). Differential roles of M1 and M2 microglia in neurodegenerative diseases. Mol. Neurobiol. 53, 1181-1194. doi: 10.1007/s12035-014-9070-5
174. Teismann, P., Sathe, K., Bierhaus, A., Leng, L., Martin, H. L., Bucala, R., et al. (2012). Receptor for advanced glycation endproducts (RAGE) deficiency protects against MPTP toxicity. Neurobiol. Aging 33, 2478-2490. doi: 10.1016/j.neurobiolaging.2011.12.006
175. Tentillier, N., Etzerodt, A., Olesen, M. N., Rizalar, F. S., Jacobsen, J., Bender, D., et al. (2016). Anti-Inflammatory modulation of microglia via CD163-targeted glucocorticoids protects dopaminergic neurons in the 6-OHDA Parkinson's disease model. J. Neurosci. 36, 9375-9390. doi: 10.1523/JNEUROSCI.1636-16.2016
176. Thomas, B., and Beal, M. F. (2007). Parkinson's disease. Hum. Mol. Genet. 16, 183-194. doi: 10.1093/hmg/ddm159
177. Thornalley, P. J. (1993). The glyoxalase system in health and disease. Mol. Aspects Med. 14, 287-371. doi: 10.1016/0098-2997(93)90002-U
178. Tóbon-Velasco, J. C., Cuevas, E., and Torres-Ramos, M. A. (2014). Receptor for AGEs (RAGE) as mediator of NF-kB pathway activation in neuroinflammation and oxidative stress. CNS Neurol. Disord. Drug Targets 13, 1615-1626. doi: 10.2174/1871527313666140806144831
179. Torres, G. E., Carneiro, A., Seamans, K., Fiorentini, C., Sweeney, A., Yao, W. D., et al. (2003). Oligomerization and trafficking of the human dopamine transporter. Mutational analysis identifies critical domains important for the functional expression of the transporter. J. Biol. Chem. 278, 2731-2739. doi: 10.1074/jbc. M201926200
180. Trezzi, J. P., Galozzi, S., Jaeger, C., Barkovits, K., Brockmann, K., Maetzler, W., et al. (2017). Distinct metabolomic signature in cerebrospinal fluid in early Parkinson's disease. Mov. Disord. 32, 1401-1408. doi: 10.1002/mds.27132
181. Tsujii, S., Ishisaka, M., and Hara, H. (2015). Modulation of endoplasmic reticulum stress in Parkinson's disease. Eur. J. Pharmacol. 765, 154-156. doi: 10.1016/j.ejphar.2015.08.033
182. Tysnes, O. B., and Storstein, A. (2017). Epidemiology of Parkinson's disease. J. Neural Transm. 124, 901-905. doi: 10.1007/s00702-017-1686-y
183. Uchiki, T., Weikel, K. A., Jiao, W., Shang, F., Caceres, A., Pawlak, D., et al. (2012). Glycation-altered proteolysis as a pathobiologic mechanism that links dietary glycemic index, aging, and age-related disease (in nondiabetics). Aging Cell 11, 1-13. doi: 10.1111/j.1474-9726.2011.00752.x
184. Ulrich, P., and Cerami, A. (2001). Protein glycation, diabetes, and aging. Recent Prog. Horm. Res. 56, 1-21. doi: 10.1210/rp.56.1.1
185. van Kooyk, Y., and Rabinovich, G. A. (2008). Protein-glycan interactions in the control of innate and adaptive immune responses. Nat. Immunol. 9, 593-601. doi: 10.1038/ni.f.203
186. Viana, S. D., Valero, J., Rodrigues-Santos, P., Couceiro, P., Silva, A. M., Carvalho, F., et al. (2016). Regulation of striatal astrocytic receptor for advanced glycation end-products variants in an early stage of experimental Parkinson's disease. J. Neurochem. 138, 598-609. doi: 10.1111/jnc.13682
187. Vicente Miranda, H., El-Agnaf, O. M., and Outeiro, T. F. (2016). Glycation in Parkinson's disease and Alzheimer's disease. Mov. Disord. 31, 782-790. doi: 10.1002/mds.26566
188. Vicente Miranda, H., Szego, éM., Oliveira, L. M., Breda, C., Darendelioglu, E., de Oliveira, R. M., et al. (2017). Glycation potentiates a-synuclein-associated neurodegeneration in synucleinopathies. Brain 140, 1399-1419. doi: 10.1093/brain/awx056
189. Videira, P. A., Amado, I. F., Crespo, H. J., Algueró, M. C., Dall'Olio, F., Cabral, M. G., et al. (2008). Surface alpha 2-3-and alpha 2-6-sialylation of human monocytes and derived dendritic cells and its influence on endocytosis. Glycoconj. J. 25, 259-268. doi: 10.1007/s10719-007-9092-6
190. Vijitruth, R., Liu, M., Choi, D. Y., Nguyen, X. V., Hunter, R. L., and Bing, G. (2006). Cyclooxygenase-2 mediates microglial activation and secondary dopaminergic cell death in the mouse MPTP model of Parkinson's disease. J. Neuroinflammation 3:6
191. Vincent, A., Briggs, L., Chatwin, G. F. J., Emery, E., Tomlins, R., Oswald, M., et al. (2012). Parkin-induced defects in neurophysiology and locomotion are generated by metabolic dysfunction and not oxidative stress. Hum. Mol. Genet. 21, 1760-1769. doi: 10.1093/hmg/ddr609
192. Vitte, J., Michel, B. F., Bongrand, P., and Gastaut, J. L. (2004). Oxidative stress level in circulating neutrophils is linked to neurodegenerative diseases. J. Clin. Immunol. 24, 683-692. doi: 10.1007/s10875-004-6243-4
193. Wang, H., Liu, J., and Wu, L. (2009). Methylglyoxal-induced mitochondrial dysfunction in vascular smooth muscle cells. Biochem. Pharmacol. 77, 1709-1715. doi: 10.1016/j.bcp.2009.02.024
194. Wang, Y. D., Bao, X. Q., Xu, S., Yu, W. W., Cao, S. N., Hu, J. P., et al. (2016). A novel Parkinson's disease drug candidate with potent anti-neuroinflammatory effects through the Src signaling pathway. J. Med. Chem. 59, 9062-9079. doi: 10.1021/acs.jmedchem.6b00976
195. Wang, X., Feng, Z., Wang, X., Yang, L., Han, S., Cao, K., et al. (2016). O-GlcNAcase deficiency suppresses skeletal myogenesis and insulin sensitivity in mice through the modulation of mitochondrial homeostasis. Diabetologia 59, 1287-1296. doi: 10.1007/s00125-016-3919-2
196. Wani, W. Y., Ouyang, X., Benavides, G. A., Redmann, M., Cofield, S. S., Shacka, J. J., et al. (2017). O-GlcNAc regulation of autophagy and a-synuclein homeostasis; implications for Parkinson's disease. Mol. Brain 10:32. doi: 10.1186/s13041-017-0311-1
197. West, A. B., and Maidment, N. T. (2004). Genetics of parkin-linked disease. Hum. Genet. 114, 327-336. doi: 10.1007/s00439-003-1074-6
198. Witoelar, A., Jansen, I. E., Wang, Y., Desikan, R. S., Gibbs, J. R., Blauwendraat, C., et al. (2017). Genome-wide pleiotropy between Parkinson disease and autoimmune diseases. JAMA Neurol. 74, 780-792. doi: 10.1001/jamaneurol.2017.0469
199. Wong, A. S., Lee, R. H., Cheung, A. Y., Yeung, P. K., Chung, S. K., Cheung, Z. H., et al. (2011). Cdk5-mediated phosphorylation of endophilin B1 is required for induced autophagy in models of Parkinson's disease. Nat. Cell Biol. 13, 568-579. doi: 10.1038/ncb2217
200. Wu, D. C., Jackson-Lewis, V., Vila, M., Tieu, K., Teismann, P., Vadseth, C., et al. (2002). Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine mouse model of Parkinson disease. J. Neurosci. 22, 1763-1771. doi: 10.1523/JNEUROSCI.22-05-01763.2002
201. Wu, G., Lu, Z. H., Kulkarni, N., Amin, R., and Ledeen, R. W. (2011). Mice lacking major brain gangliosides develop parkinsonism. Neurochem. Res. 36, 1706-1714. doi: 10.1007/s11064-011-0437-y
202. Xiao, X., Yuan, J., Haïk, S., Cali, I., Zhan, Y., Moudjou, M., et al. (2013). Glycoform-selective prion formation in sporadic and familial forms of prion disease. PLoS One 8:e58786. doi: 10.1371/journal.pone.0058786
203. Xie, B., Lin, F., Ullah, K., Peng, L., Ding, W., Dai, R., et al. (2015). A newly discovered neurotoxin ADTIQ associated with hyperglycemia and Parkinson's disease. Biochem. Biophys. Res. Commun. 459, 361-366. doi: 10.1016/j.bbrc.2015.02.069
204. Xu, X. Y., Deng, C. Q., Wang, J., Deng, X. J., Xiao, Q., Li, Y., et al. (2017). Plasma levels of soluble receptor for advanced glycation end products in Alzheimer's disease. Int. J. Neurosci. 127, 454-458. doi: 10.1080/00207454.2016.1193861
205. Xu, Y., Toure, F., Qu, W., Lin, L., Song, F., Shen, X., et al. (2010). Advanced glycation end product (AGE)-receptor for AGE (RAGE) signaling and up-regulation of Egr-1 in hypoxic macrophages. J. Biol. Chem. 285, 23233-23240. doi: 10.1074/jbc. M110.117457
206. Xue, M., Rabbani, N., Momiji, H., Imbasi, P., Anwar, M. M., Kitteringham, N., et al. (2012). Transcriptional control of glyoxalase 1 by Nrf2 provides a stress-responsive defence against dicarbonyl glycation. Biochem. J. 443, 213-222. doi: 10.1042/BJ20111648
207. Yamagishi, S., Nakamura, N., Suematsu, M., Kaseda, K., and Matsui, T. (2015). Advanced glycation end products: a molecular target for vascular complications in diabetes. Mol. Med. 21(Suppl. 1), S32-S40. doi: 10.2119/molmed.2015.00067
208. Yan, S. F., Ramasamy, R., and Schmidt, A. M. (2010). Soluble RAGE: therapy and biomarker in unraveling the RAGE axis in chronic disease and aging. Biochem. Pharmacol. 79, 1379-1386. doi: 10.1016/j.bcp.2010.01.013
209. Yoshino, H., Nakagawa-Hattori, Y., Kondo, T., and Mizuno, Y. (1992). Mitochondrial complex I and II activities of lymphocytes and platelets in Parkinson's disease. J. Neural Transm. Park. Dis. Dement. Sect. 4, 27-34. doi: 10.1007/BF02257619
210. Zhao, L., Feng, Z., Zou, X., Cao, K., Xu, J., and Liu, J. (2014). Aging leads to elevation of O-GlcNAcylation and disruption of mitochondrial homeostasis in retina. Oxid. Med. Cell. Longev. 2014:425705. doi: 10.1155/2014/425705
211. Zheng, B., Liao, Z., Locascio, J. J., Lesniak, K. A., Roderick, S. S., Watt, M. L., et al. (2010). PGC-1a, a potential therapeutic target for early intervention in Parkinson's disease. Sci. Transl. Med. 2:52ra73. doi: 10.1126/scitranslmed.3001059
212. Zhu, J. H., Horbinski, C., Guo, F., Watkins, S., Uchiyama, Y., and Chu, C. T. (2007). Regulation of autophagy by extracellular signal-regulated protein kinases during 1-methyl-4-phenylpyridinium-induced cell death. Am. J. Pathol. 170, 75-86. doi: 10.2353/ajpath.2007.060524
213. Zis, P., Erro, R., Walton, C. C., Sauerbier, A., and Chaudhuri, K. R. (2015). The range and nature of non-motor symptoms in drug-naive Parkinson's disease patients: a state-of-the-art systematic review. NPJ Parkinsons Dis. 1:15013. doi: 10.1038/npjparkd.2015.13